U.S. drugmaker Pfizer Inc. said the company was shutting down two manufacturing plants in India that make generic injectables such as penicillin in response to falling demand.
RedHill Biopharma’s combination antibiotic Talicia met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine.
The U.S. FDA approved Aries Pharmaceuticals Inc.’s Aemcolo (rifamycin) for the treatment of adult patients with Travelers’ Diarrhea caused by non-invasive strains of Escherichia coli.
Antibiotics are used far more in some countries than in others, a survey by the World Health Organization showed, suggesting that urgent action was needed to slash unnecessary consumption of the medicines.
Foamix Pharmaceuticals’ experimental foam treatment FMX103 for rosacea met the main goals of two late-stage studies.
The EMA’s risk assessment committee recommended restrictions on the use of the broad-spectrum antibiotics.
The U.S. FDA approved Paratek Pharmaceuticals Inc.’s Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia and acute skin and skin structure infections.
The Indian government banned 328 combination drugs in a blow to both domestic and foreign pharmaceutical firms, but the ban has been cheered by health activists worried about growing antibiotic resistance due to the misuse of medicines.
Foamix Pharmaceuticals Ltd.’s lead drug for treating moderate-to-severe acne met the main goals of the company’s third late-stage study, sending its shares up 57 percent in extended trading.